Fda accepts resubmission of bla for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (ta-tma) and assigns late september pdufa date

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that the u.s. food and drug administration (fda) has accepted for review the resubmission of the biologics license application (bla) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (ta-tma). the resubmission was classified as a class 2 resubmission and pursuant to the prescription drug user fee act (pdufa) has been assigned a target action date for the fda de.
STEM Ratings Summary
STEM Quant Ranking